Status:
UNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)
Lead Sponsor:
National Cancer Institute, Naples
Conditions:
Sarcoma
Eligibility:
All Genders
Brief Summary
MGMT study is a retrospective, non-profit, multi-center, observational study. The scientific objective of this study is to investigate whether MGMT expression or MGMT promoter methylation may represen...
Detailed Description
Sarcomas comprise a group of rare malignancies that are challenging to treat. Incidence of sarcoma is 15,000 annually in the U.S. \[1\] with a high case fatality rate. Up to one fourth of patients wit...
Eligibility Criteria
Inclusion
- \- Patients with a histological diagnosis of metastatic LMS and SFT from 2010 to 2020, previously treated with dacarbazine alone or with anthracyclines as first line of chemotherapy.
Exclusion
- Patients with histological diagnosis of metastatic LMS and SFT, received before 2010.
- Patients with histological diagnosis of metastatic LMS and SFT from 2010 to 2020, never treated with dacarbazine
- Patients with a histological diagnosis of metastatic LMS and SFT from 2010 to 2020, previously treated with dacarbazine alone or with anthracyclines as the first line of chemotherapy, of which, however, there is no tissue sample
Key Trial Info
Start Date :
January 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 20 2025
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04893356
Start Date
January 20 2021
End Date
January 20 2025
Last Update
October 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute of Naples
Naples, Campania, Italy, 80131